-
²úÆ·Å·ÃËCEÈÏÖ¤½¨æÅºÍÒªÇó
Å·ÃËCEÈÏÖ¤ÊDzúÆ·½øÈëÅ·ÖÞÊг¡µÄÇ¿ÖÆÐÔÈÏÖ¤ÒªÇ󣬣¬£¬£¬£¬ÌåÏÖ²úÆ·ÇкÏÅ·Ã˵ÄÏà¹Ø¹æÔòºÍ±ê×¼ÒªÇ󡣡£¹ØÓÚÏ£Íû½«²úÆ·ÏúÍùÅ·ÃËÊг¡µÄÖÆÔìÉ̺ÍÈë¿ÚÉÌÀ´Ëµ£¬£¬£¬£¬£¬CEÈÏÖ¤²»µ«ÊÇÊг¡×¼ÈëµÄÐëÒªÌõ¼þ£¬£¬£¬£¬£¬¸üÊÇÌáÉý²úÆ·¾ºÕùÁ¦ºÍÏûºÄÕßÐÅÈεÄÖ÷ÒªÊֶΡ£¡£ÒÔÏÂÊÇһƪ¹ØÓÚ²úÆ·Å·ÃËCEÈÏÖ¤½¨æÅºÍÒªÇóµÄ³¤ÎÄÕÂÕýÎÄ¡£¡£Ò»¡¢CEÈÏÖ¤µÄÖ÷ÒªÐÔCEÈÏÖ¤£¨Conformit¨¦ Europ¨¦enne£©ÊDzúÆ·½øÈëÅ·ÃËÊг¡µÄ¼°¸ñ±ê¼Ç£¬£¬£¬£¬£¬ËüÌåÏÖ²úÆ·ÔÚÉè¼ÆºÍÉú²úÀú³ÌÖÐÒÑÇкÏÅ·Ã˹ØÓÚÇå¾²¡¢¿µ½¡¡¢»·±£µÈ·½ÃæµÄ¹æÔòÒªÇ󣬣¬£¬£¬£¬²¢ÇÒ²úÆ·ÊÊÓÃÓÚÅ·ÃËÊг¡¡£¡£CEÈÏÖ¤µÄÄ¿µÄÊÇΪÁ˱£»£»£»£»£»£»¤ÏûºÄÕß¡¢ÇéÐÎÒÔ¼°ÆäËûÓû§µÄ¿µ½¡ºÍÇå¾²£¬£¬£¬£¬£¬Í¬Ê±Ôö½øÅ·ÃËÄÚ²¿Êг¡µÄ×ÔÓÉÁ÷ͨ¡£¡£»£»£»£»£»£»ñµÃCEÈÏÖ¤µÄ²úÆ·£¬£¬£¬£¬£¬Òâζ×ÅÆäÒѾͨ¹ýÁËÅ·ÃËÏà¹ØÖ¸ÁîµÄ²âÊÔºÍÆÀ¹À£¬£¬£¬£¬£¬ÇкÏÁËÅ·Ã˵ÄÇå¾²¡¢¿µ½¡¡¢»·±£ºÍÏûºÄÕß±£»£»£»£»£»£»¤µÈ¹æÔòÒªÇ󡣡£Õâ²»µ«ÓÐÖúÓÚ²úƷ˳Ëì½ø¡¤¡¤¡¤
172
-
FDAÑé³§Á÷³ÌÏêϸڹÊÍ
FDA£¨Food and Drug Administration£©Á¥ÊôÓÚÃÀ¹ú¿µ½¡ÓëÈËÀàЧÀͲ¿£¨DHHS£©£¬£¬£¬£¬£¬ÈÏÕæÌìÏÂÒ©Æ·¡¢Ê³Îï¡¢ÉúÎïÖÆÆ·¡¢»¯×±Æ·¡¢ÊÞÒ©¡¢Ò½ÁÆÆ÷еÒÔ¼°Õï¶ÏÓÃÆ·µÈµÄÖÎÀí¡£¡£FDAÑé³§ÊÇÈ·±£ÕâЩ²úÆ·Çå¾²ÐÔºÍÓÐÓÃÐÔµÄÖ÷ÒªÊֶΣ¬£¬£¬£¬£¬Í¨¹ýÑÏ¿áµÄÉó²éºÍ²âÊÔ£¬£¬£¬£¬£¬È·±£²úÆ·ÔÚ½øÈëÊг¡Ç°ÇкÏÑÏ¿áµÄÇå¾²ÐÔ±ê×¼£¬£¬£¬£¬£¬´Ó¶øÓÐÓñ£»£»£»£»£»£»¤ÏûºÄÕߵĿµ½¡¡£¡£ÒÔÏÂÊǶÔFDAÑé³§Á÷³ÌµÄÏêϸڹÊÍ¡£¡£Ò»¡¢È·¶¨²úÆ··ÖÀàºÍÖÖ±ðFDAÈÏÖ¤³ÌÐòµÄµÚÒ»²½ÊÇÈ·¶¨²úÆ·µÄ·ÖÀàºÍÖֱ𡣡£²î±ðÀà±ðµÄ²úÆ·ÐèÒªÖª×ã²î±ðµÄ±ê×¼ºÍ¹æÔò£¬£¬£¬£¬£¬Òò´Ë£¬£¬£¬£¬£¬×¼È·µØÈ·¶¨²úÆ·ÖÖ±ðÖÁ¹ØÖ÷Òª¡£¡£FDAÖ÷Òª½«²úÆ··ÖΪÈýÀࣺҩƷ¡¢Ò½ÁÆÆ÷еºÍʳÎï/»¯×±Æ·¡£¡£Ò©Æ·£º°üÀ¨´¦·½Ò©¡¢·Ç´¦·½Ò©£¨OTC£©ºÍÉúÎïÒ©Æ·µÈ¡£¡£Ò©Æ·µÄÑé³§ÒÀ¾ÝÊÇ21 CFRÒ©Æ·¹æÔòÕ½ڡ£¡£Ò½ÁÆÆ÷е£º°üÀ¨ÖÖÖÖÒ½ÁÆ×°±¸¡¢Æ÷е¡¢¹¤¾ß¡¢Ö²ÈëÎï¡¢ÌåÍâÕï¶Ï¡¤¡¤¡¤
592
-
MDL×¢²áµÄÉóºËºÍÆÀ¹À?Á÷³Ì
MDL£¨Medical Device License£©×¢²áµÄÉóºËºÍÆÀ¹ÀÁ÷³ÌÊÇÈ·±£Ò½ÁÆÆ÷еÔÚ¼ÓÄôóÊг¡ÉÏÇå¾²¡¢ÓÐÓÃÇÒÇкϹæÔòÒªÇóµÄÒªº¦°ì·¨¡£¡£ÕâÒ»Àú³ÌÉæ¼°¶à¸ö»·½Ú£¬£¬£¬£¬£¬´Ó×¼±¸ÉêÇë×ÊÍÆ²â×îÖÕ»ñµÃÈÏÖ¤£¬£¬£¬£¬£¬Ã¿Ò»²½¶¼ÖÁ¹ØÖ÷Òª¡£¡£±¾ÎĽ«ÏêϸÐðÊöMDL×¢²áµÄÉóºËºÍÆÀ¹ÀÁ÷³Ì£¬£¬£¬£¬£¬×ÊÖúÒ½ÁÆÆ÷ÐµÖÆÔìÉ̸üºÃµØÃ÷È·ºÍÓ¦¶ÔÕâÒ»ÖØ´óÀú³Ì¡£¡£Ò»¡¢×¼±¸ÉêÇë×ÊÁÏMDL×¢²áµÄµÚÒ»²½ÊÇ×¼±¸ÉêÇë×ÊÁÏ¡£¡£ÉêÇëÕßÐèҪƾ֤¼ÓÄôóÎÀÉú²¿£¨Health Canada£©µÄÒªÇ󣬣¬£¬£¬£¬Ìá½»ÍêÕûÇÒ׼ȷµÄÉêÇëÎļþ¡£¡£ÕâЩÎļþ°üÀ¨µ«²»ÏÞÓÚ£ºÉêÇë±í£ºÏêϸÌîд²úÆ·ÐÅÏ¢ºÍ¹«Ë¾ÐÅÏ¢£¬£¬£¬£¬£¬È·±£ËùÓÐÄÚÈÝ׼ȷÎÞÎ󡣡£ÊÖÒÕÎļþ£ºÕâÊÇÉêÇëµÄ½¹µã²¿·Ö£¬£¬£¬£¬£¬°üÀ¨²úÆ·µÄÉè¼ÆÔÀí¡¢ÊÖÒÕ¹æ¸ñ¡¢ÐÔÄÜÊý¾Ý¡¢Ê¹ÓÃ˵Ã÷Ê顢Σº¦ÆÊÎö±¨¸æµÈ¡£¡£ÊÖÒÕÎļþ±ØÐèÖÜÈ«ÇÒÏ꾡£¬£¬£¬£¬£¬ÒÔ֤ʵ²úÆ·µÄÇå¾²ÐÔºÍÓÐÓÃÐÔ¡£¡£ÖÊÁ¿ÖÎÀíϵͳÎļþ£ºÖ¤ÊµÉêÇëÕ߾߱¸¡¤¡¤¡¤
257
-
¹ú¼ÒÒ½ÁÆÆ÷еע²áЧÀÍ£ºÒ»Õ¾Ê½½â¾ö¼Æ»®
ÔÚµ±½ñÒ½ÁƿƼ¼ÈÕÐÂÔÂÒìµÄʱ´ú£¬£¬£¬£¬£¬Ò½ÁÆÆ÷е×÷ΪҽÁÆÏµÍ³ÖеÄÖ÷Òª×é³É²¿·Ö£¬£¬£¬£¬£¬ÆäÇå¾²ÐÔ¡¢ÓÐÓÃÐԺͺϹæÐÔÖ±½Ó¹ØÏµµ½»¼ÕßµÄÉúÃü¿µ½¡ÓëÒ½ÁÆÖÊÁ¿¡£¡£Òò´Ë£¬£¬£¬£¬£¬Ò½ÁÆÆ÷еµÄ×¢²áÁ÷³ÌÏÔµÃÓÈΪÖ÷Òª£¬£¬£¬£¬£¬Ëü²»µ«ÊDzúÆ·½øÈëÊг¡µÄͨÐÐÖ¤£¬£¬£¬£¬£¬¸üÊǰü¹Ü¹«ÖÚ¿µ½¡Çå¾²µÄ·ÀµØ¡£¡£¹ú¼ÒÒ½ÁÆÆ÷еע²áЧÀÍ£¬£¬£¬£¬£¬×÷ΪÅþÁ¬Ò½ÁÆÆ÷еÑз¢ÕßÓëî¿Ïµ»ú¹¹µÄÇÅÁº£¬£¬£¬£¬£¬Ìṩһվʽ½â¾ö¼Æ»®£¬£¬£¬£¬£¬Ö¼ÔÚ¼ò»¯×¢²áÁ÷³Ì¡¢Ìá¸ßЧÂÊ¡¢È·±£ºÏ¹æ£¬£¬£¬£¬£¬ÎªÒ½ÁÆÆ÷еµÄ¿ìËÙÉÏÊÐºÍÆÕ±éÓ¦ÓõÓÚ¨¼áʵ»ù´¡¡£¡£Ò»¡¢Ò»Õ¾Ê½½â¾ö¼Æ»®µÄ½¹µã¼ÛÖµ¹ú¼ÒÒ½ÁÆÆ÷еע²áЧÀ͵Äһվʽ½â¾ö¼Æ»®£¬£¬£¬£¬£¬Æä½¹µãÔÚÓÚÕûºÏ×ÊÔ´¡¢ÓÅ»¯Á÷³Ì¡¢Ìṩרҵָµ¼£¬£¬£¬£¬£¬È·±£Ò½ÁÆÆ÷е´ÓÑз¢µ½ÉÏÊеÄÈ«Á´Ìõ˳³©ÎÞ×è¡£¡£ÕâһЧÀÍģʽµÄÍÆ³ö£¬£¬£¬£¬£¬ÓÐÓýâ¾öÁËÆóÒµÔÚ×¢²áÀú³ÌÖÐÃæÁÙµÄÖî¶àÔÖÌ⣬£¬£¬£¬£¬Èç¹æÔòÃ÷È·²»Í¸³¹¡¢×ÊÁÏ×¼±¸²»³ä·Ö¡¢ÉóÅúÖÜÆÚ³¤µÈ£¬£¬£¬£¬£¬¼«´óµØÌáÉýÁË×¢²áÀÖ³ÉÂÊ£¬£¬£¬£¬£¬Ëõ¶ÌÁ˲úÆ·ÉÏÊÐʱ¼ä¡£¡£¶þ¡¢È«¡¤¡¤¡¤
340
-
CEÈÏÖ¤×Éѯ£ºÇå¾²ÈÏÖ¤±ê¼Ç¸ÅÊö
CEÈÏÖ¤£¬£¬£¬£¬£¬ÕâÒ»Ô´×ÔÅ·ÖÞµÄÇå¾²ÈÏÖ¤±ê¼Ç£¬£¬£¬£¬£¬×Ô½µÉúÒÔÀ´±ã³ÉΪÁ˲úÆ·½øÈëÅ·ÖÞÊг¡µÄ¡°»¤ÕÕ¡±¡£¡£Ëü²»µ«´ú±íÁ˲úÆ·ÇкÏÅ·ÖÞ¾¼ÃÇø£¨EEA£©µÄ¿µ½¡¡¢Çå¾²ºÍ»·±£¹æÔòÒªÇ󣬣¬£¬£¬£¬¸üÊÇÖÆÔìÉÌÏòÈ«ÇòÏûºÄÕßÔÊÐí²úÆ·Çå¾²ÓëÖÊÁ¿µÄ±ê¼Ç¡£¡£±¾ÎĽ«ÉîÈë̽ÌÖCEÈÏÖ¤µÄÅä¾°¡¢ÒâÒå¡¢Á÷³Ì¼°ÆäÔÚ²î±ðÁìÓòµÄÓ¦Ó㬣¬£¬£¬£¬ÒÔÆÚΪÓÐÒâ½ø¾üÅ·ÖÞÊг¡µÄÆóÒµÌṩÖÜÈ«µÄÖ¸µ¼¡£¡£CEÈÏÖ¤µÄÅä¾°ÓëÒâÒåCEÈÏÖ¤£¬£¬£¬£¬£¬È«³Æ¡°Conformit¨¦ Europ¨¦enne¡±£¬£¬£¬£¬£¬¼´Å·ÖÞ¼°¸ñÈÏÖ¤£¬£¬£¬£¬£¬ÊÇÅ·ÖÞÅäºÏÌ壨½ñÅ·ÃË£©ÎªÁ˰ü¹ÜÏûºÄÕßÇå¾²¡¢Ôö½øÉÌÒµ×ÔÓÉ»¯¶øÉèÁ¢µÄÒ»ÖÖÇ¿ÖÆÐÔ²úÆ·ÈÏÖ¤ÖÆ¶È¡£¡£¸ÃÈÏÖ¤ÖÆ¶ÈʼÓÚ20ÊÀ¼Í80ÄêÔ£¬£¬£¬£¬£¬Ëæ×ÅÅ·ÖÞÒ»Ì廯Àú³ÌµÄ¼ÓËÙ£¬£¬£¬£¬£¬CE±ê¼ÇÖð½¥³ÉΪ²úÆ·½øÈëÅ·ÖÞÊг¡µÄ±Ø±¸Ìõ¼þ¡£¡£Ëü±ê¼Ç×ŲúÆ·ÒÑͨ¹ýÁËÅ·ÖÞÏà¹ØÖ¸ÁîµÄÇå¾²ÆÀ¹À£¬£¬£¬£¬£¬ÎÞÐèÔÙ½ÓÊܸ÷³ÉÔ±¹úµÄÖØ¸´¼ì²â£¬£¬£¬£¬£¬´Ó¶øÊµÏÖÁËÉÌÆ·ÔÚÅ·ÖÞÊг¡µÄ×ÔÓÉÁ÷¡¤¡¤¡¤
312
-
FDA510KÈÏÖ¤ÐèҪ׼±¸Ê²Ã´ÖÊÁÏ
ÔÚ̽ÌÖFDA 510KÈÏÖ¤ËùÐè×¼±¸µÄÖÊÁÏʱ£¬£¬£¬£¬£¬ÎÒÃÇÊ×ÏÈÐèÒªÏàʶFDA£¨ÃÀ¹úʳÎïÒ©Æ·¼àÊÓÖÎÀí¾Ö£©¹ØÓÚÒ½ÁÆÆ÷еµÄ·ÖÀàºÍî¿ÏµÒªÇ󡣡£FDA½«Ò½ÁÆÆ÷е·ÖΪÈýÀࣺIÀàΪµÍΣº¦£¬£¬£¬£¬£¬Í¨³£»£»£»£»£»£¿íÃâ510KÈÏÖ¤£¬£¬£¬£¬£¬Ö»Ðè¾ÙÐÐÒ»Ñùƽ³£×¢²á£»£»£»£»£»£»IIÀàΪÖеÈΣº¦£¬£¬£¬£¬£¬ÐèÒªÌá½»510KÉêÇëÒÔ֤ʵÐÂ×°±¸ÓëÒÑÉÏÊÐ×°±¸¾ßÓС°ÊµÖʵÈͬÐÔ¡±£»£»£»£»£»£»IIIÀàΪ¸ßΣº¦£¬£¬£¬£¬£¬ÐèÒªÌá½»PMA£¨Premarket Approval£©ÉêÇ룬£¬£¬£¬£¬¾ÙÐиüΪÑÏ¿áµÄÉóºË¡£¡£±¾ÎĽ«ÖصãÌÖÂÛIIÀàÒ½ÁÆÆ÷еÉêÇë510KÈÏ֤ʱËùÐè×¼±¸µÄÖÊÁÏ¡£¡£Ò»¡¢510KÉêÇë¸ÅÊö510KÈÏÖ¤ÊÇFDAÕë¶ÔIIÀàÒ½ÁÆÆ÷еÉÏÊÐǰµÄÒ»ÖÖÉóÅú³ÌÐò£¬£¬£¬£¬£¬Ö¼ÔÚÈ·±£ÐÂ×°±¸ÔÚÇå¾²ÐÔ¡¢ÓÐÓÃÐÔ·½ÃæÓëÒÑÉÏÊеÄͬÀà×°±¸Ï൱¡£¡£ÉêÇëÕßÐèÒªÌύһϵÁÐÎļþ£¬£¬£¬£¬£¬ÒÔ֤ʵвúÆ·µÄʵÖʵÈͬÐÔ¡£¡£¶þ¡¢ÉêÇëÖÊÁϵÄ×¼±¸1. 510KÕªÒª¼°ÉêÇ뺯ÉêÇ뺯ÊÇÏòFDAÌá½»µÄ¡¤¡¤¡¤
299